Several clinical phase I/II studies, evaluating the safety and efficacy of JAK1 and JAK2 inhibitors in patients with relapsed/refractory B-cell lymphoma, including DLBCL are ongoing (NCT01905813, NCT01431209) (Additional file 1: Table S6) or in planning [109, 317, 318]. The gene discussed is JAK1; the disease is B-cell non-Hodgkin lymphoma.